# Capricor Therapeutics

its lead asset Deramiocel (formerly CAP-1002), an allogeneic cardiosphere-derived cell therapy whose benefit in Duchenne muscular dystrophy is believed to work partly through paracrine exosome secretion, has a Biologics License Application now scheduled for FDA Advisory Committee review on July 29, 2026,…

Source: https://en.bioecon.ru/companies/capricor-therapeutics/
Updated: 2026-08-15

- Country: United States
- Ticker: CAPR

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $278.6 million in cash, cash equivalents and marketable securities as of March 31, 2026 | https://www.biospace.com/press-releases/capricor-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update, https://www.biospace.com/press-releases/capricor-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-update, https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001104659-26-027037/0001104659-26-027037.pdf |
| Capacity | Scaling to approximately 2,000–2,500 patients per year or 10,000 doses annually at full capacity upon validation | https://www.biospace.com/press-releases/capricor-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update, https://www.biospace.com/press-releases/capricor-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-update, https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001104659-26-027037/0001104659-26-027037.pdf |
| Certification | GMP compliant manufacturing facility in San Diego successfully completed an FDA Pre-License Inspection | https://www.biospace.com/press-releases/capricor-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update, https://www.biospace.com/press-releases/capricor-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-update, https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001104659-26-027037/0001104659-26-027037.pdf, https://www.sec.gov/Archives/edgar/data/1133869/000110465926025657/capr-20260310xex99d1.htm |
| Regulatory approval | Deramiocel has Orphan Drug, RMAT, ATMP, and Rare Pediatric Disease designations; BLA under FDA review with PDUFA date of August 22, 2026 | https://www.biospace.com/press-releases/capricor-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update, https://www.biospace.com/press-releases/capricor-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-update, https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001104659-26-027037/0001104659-26-027037.pdf, https://www.sec.gov/Archives/edgar/data/1133869/000110465926025657/capr-20260310xex99d1.htm |
| Production site | GMP manufacturing facility in San Diego, California | https://www.biospace.com/press-releases/capricor-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update, https://www.biospace.com/press-releases/capricor-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-update, https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001104659-26-027037/0001104659-26-027037.pdf |
| Headcount | Approximately 247-299 employees as of mid-2026 [medium confidence] | https://altindex.com/ticker/capr/employees-linkedin, https://finance.yahoo.com/quote/CAPR/profile/ |
| Revenue | $0 revenue for the first quarter of 2026 and for the full year 2025 | https://www.biospace.com/press-releases/capricor-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update, https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001104659-26-027037/0001104659-26-027037.pdf |

Independent sources: altindex.com, biospace.com, finance.yahoo.com, sec.gov

## Technologies

- [Exosome therapy & extracellular vesicles](https://en.bioecon.ru/technology/exosome-therapy-extracellular-vesicles/)